Investment Thesis
Shattuck Labs is a development-stage pharmaceutical company with zero commercial revenue and deteriorating operating performance, burning $13.4M quarterly with only ~6-7 quarters of cash runway at current rates. While the balance sheet remains strong with $90.4M cash and zero debt, the absence of revenue generation and lack of insider buying activity signal significant execution risk and uncertainty around pathway to profitability.
Strengths
- Strong cash position of $90.4M provides runway for operations
- Zero debt and exceptional liquidity ratios (22.06x current ratio)
- Declining losses with EPS improvement of 53% YoY shows operational discipline
Risks
- Virtually zero revenue with 82.5% YoY decline indicates failed commercialization efforts
- Operating cash burn of $13.4M per quarter with limited runway (est. 6-7 quarters)
- Development-stage pharma with high execution risk and uncertain regulatory pathway
- Zero insider Form 4 filings in 90 days suggests no insider confidence
Key Metrics to Watch
- Revenue traction and clinical trial/regulatory approval milestones
- Quarterly cash burn rate and updated cash runway estimates
- Operating loss trajectory and path to cash flow breakeven
Financial Metrics
Revenue
0.0
Net Income
-14.8M
EPS (Diluted)
$-0.13
Free Cash Flow
-13.5M
Total Assets
102.1M
Cash
90.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-15.4%
ROA
-14.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
22.06x
Quick Ratio
22.06x
Debt/Equity
0.00x
Debt/Assets
6.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:17:27.530513 |
Data as of: 2026-03-31 |
Powered by Claude AI